Cochlear's (ASX:COH) Market Moves: Why This Healthcare Stock is on the Radar

3 min read | February 20, 2025 12:00 AM AEDT | By Team Kalkine Media

Cochlear's (ASX:COH) Market Moves: Why This Healthcare Stock is on the Radar — Image source: shutterstock

A Leader in Hearing Solutions

Founded in 1981 and headquartered in Sydney, Cochlear specializes in advanced hearing implants. The company designs, manufactures, and distributes a range of implantable devices to improve hearing for those with severe auditory impairments. With over 750,000 devices delivered globally and a workforce of 5,000+ employees spanning more than 50 countries, Cochlear continues to be a major player in the medical technology space.

The company’s mission revolves around enhancing the quality of life for individuals with hearing-related conditions. Given the increasing demand for innovative healthcare solutions, Cochlear's market position remains strong.

Why Healthcare Stocks Remain Attractive

The healthcare sector has historically been resilient, even during economic downturns. Over the past five years, the S&P/ASX200 Healthcare Index (ASX:XHJ) has underperformed the broader ASX 200, with an annualized return of -1.09% compared to 3.83%. However, healthcare companies like Cochlear have unique strengths that set them apart.

Consistent Revenue Streams

Healthcare spending is often essential, making it one of the last areas where individuals cut costs, even in challenging economic times. Unlike industries that fluctuate based on commodity prices or consumer trends, healthcare companies benefit from stable and predictable revenue. Historical data shows that during financial crises, the healthcare sector tends to outperform other industries.

Long-Term Growth Potential

Global healthcare spending continues to rise, particularly in the U.S., which accounts for over 40% of worldwide healthcare expenditures. Projections indicate that U.S. healthcare spending will grow at an average rate of 7% annually from 2022 to 2027, reaching an estimated US$819 billion.

Additionally, emerging healthcare segments, including digital health, data analytics, and healthcare software-as-a-service (SaaS), are expected to expand at more than 15% per year from 2024 to 2030, providing further growth opportunities for companies within the industry.

Growing Ethical Investment Trends

Sustainable investing is gaining traction, with an increasing number of investors prioritizing ethical and impact-driven opportunities. A recent Morgan Stanley survey highlighted that over 50% of investors plan to increase their exposure to sustainable investments in 2024. As a healthcare provider delivering essential services, Cochlear stands to benefit from this shift in investment preferences.

How Cochlear is Currently Valued

A common way to assess growth companies is by examining their price-to-sales (P/S) ratio. Currently, Cochlear holds a P/S ratio of 8.14x, which is below its 5-year average of 9.18x. This could indicate that the stock is trading at a lower valuation relative to its historical trends. The company has demonstrated consistent revenue growth over the past three years, which may play a role in shaping future stock performance.

While no single metric should dictate market decisions, understanding broader valuation trends provides context for how Cochlear is positioned within the healthcare sector.

With steady revenue streams, long-term growth opportunities, and increasing interest in sustainable investments, Cochlear remains a key player in the healthcare market worth keeping an eye on.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.